Australia markets closed

SNY Mar 2024 45.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.25000.0000 (0.00%)
As of 11:29AM EST. Market open.
Full screen
Previous close0.2500
Open0.5000
Bid0.0000
Ask0.0000
Strike45.00
Expiry date2024-03-15
Day's range0.2300 - 0.2500
Contract rangeN/A
Volume76
Open interestN/A
  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - January 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

  • Reuters

    Sanofi's consumer healthcare spin-off attracts private equity interest, sources say

    Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters. Buyout groups including Blackstone and CVC are considering making offers for the division, the sources said, speaking on condition of anonymity. The news comes months after Sanofi announced it was reviewing "separation scenarios" for the unit in a bid to focus on its core innovative drugs business.

  • Bloomberg

    Advent, Blackstone Among Firms Circling $20 Billion Sanofi Arm

    (Bloomberg) -- Some of the world’s largest buyout firms, including Advent International and Blackstone Inc., are circling the consumer health division of French pharmaceutical giant Sanofi ahead of a potential separation of the business, according to people familiar with the matter. Most Read from BloombergCapital One to Buy Discover for $35 Billion in Year's Biggest Deal Your 401(k) Will Be Gone Within a DecadeLargest Covid Vaccine Study Yet Finds Links to Health ConditionsStocks Fall Before Nv